Personalis, Inc. (PSNL) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 18, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Personalis, Inc. (PSNL), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Personalis, Inc., analysts forecast revenue rising from $69.53M in 2025 to $227.40M in 2030; the average estimate for 2030 earnings per share is −$0.47; with published estimates ranging from −$0.49 to −$0.45; 4 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Personalis, Inc. (PSNL) forecast — frequently asked questions
What is the analyst price target for Personalis, Inc.?
Analysts covering Personalis, Inc. (PSNL) have a consensus price target of $16.44, 11.1% above the current price of $14.80. Published targets range from $16.25 to $17.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Personalis, Inc.'s earnings?
The average analyst estimate for Personalis, Inc. (PSNL) earnings per share in 2030 is -0.47, with individual estimates between -0.49 and -0.45.
How much revenue is Personalis, Inc. expected to make?
Analysts forecast Personalis, Inc. (PSNL) revenue of $227.40M in 2030, based on 1 published estimates.
How many analysts cover PSNL?
4 analysts contribute estimates for Personalis, Inc. (PSNL). Thin coverage makes an average less reliable.
Analyst forecasts for other Medical - Diagnostics & Research stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.